ACA insurers posted good results for 2017 after hiking premiums 25%; Virginia inches closer to approving Medicaid expansion as budget talks near; an AIDS researcher is said to be the top candidate to lead the CDC.
Insurers in the Affordable Care Act (ACA) individual marketplace just had their best year in 3 years after increasing premiums by more than 25% on average last year, Politico reported. Politico analyzed financial filings for 29 regional Blue Cross Blue Shield plans and found that many insurers charged enough to cover their customers’ medical costs for the first time since the ACA marketplaces began with 10 essential health benefits. However, one good year won’t help the companies cope with the nerves they feel as they plan for 2019 amid continued uncertainty. The Trump administration ended the law’s individual mandate and a subsidy program worth billions of dollars to insurers and is expected to finalize rules making it easier to buy cheaper plans exempt from some ACA rules.
The Virginia state legislature is closer to approving a Medicaid expansion this year, and the issue will be the sticking point as the legislature goes into a special budget session April 11 to create a plan to avoid a government shutdown on June 30, Kaiser Health News reported. More than a dozen Republicans are on board in the House of Delegates, but the Senate is uncertain, even if the bill includes work requirements. However, one political analyst said that Republican State Senator Emmett Hanger, who has a record of voting independently, could convince others to switch positions.
An AIDS researcher is the top candidate to head the CDC, The Washington Post and other news outlets reported. Robert Redfield, MD, a professor of medicine at the University of Maryland School of Medicine, is well respected for his clinical work but once took controversial positions on mandatory HIV testing. His name had been floated during past Republican administrations for the top positions at the CDC and National Institutes of Health. The CDC director’s job has been vacant since January 31, when Brenda Fitzgerald, MD, resigned. A former Army physician, Redfield is director of clinical care and research at the Institute of Human Virology at the University of Maryland medical school in Baltimore. He has no apparent experience running a governmental public health agency.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More